Girth Control
Rodgers, Katie, Drug Topics
First weight loss Rx in 20 years clears the FDA
Redux (dexfenfluramine, Interneuron Pharmaceuticals), a serotonergic appetite suppressant, has received Food & Drug Administration approval for the management of obesity in patients on a reduced-calorie diet. It is approved for both initial weight loss and maintenance of weight loss, so pharmacists can expect to see it used long-term. The first appetite suppressant to clear the FDA in 20 years, dexfenfluramine has been available in Europe for more than a decade and has been used by an estimated 10 million patients.
Dexfenfluramine appears to increase serotonin levels by three different mechanisms. Robert Kushner, M.D., …
The rest of this article is only available to active members of Questia
Sign up now for a free, 1-day trial and receive full access to:
- Questia's entire collection
- Automatic bibliography creation
- More helpful research tools like notes, citations, and highlights
- Ad-free environment
Already a member? Log in now.
Questia, a part of Gale, Cengage Learning. www.questia.com
Publication information:
Article title: Girth Control.
Contributors: Rodgers, Katie - Author.
Magazine title: Drug Topics.
Volume: 140.
Issue: 10
Publication date: May 2, 1996.
Page number: 30.
© Advanstar Communications, Inc. Jan 2009.
Provided by ProQuest LLC. All Rights Reserved.
This material is protected by copyright and, with the exception of fair use, may not be further copied, distributed or transmitted in any form or by any means.
One moment ...
- Georgia
- Arial
- Times New Roman
- Verdana
- Courier/monospaced
Reset